Home List your patent My account Help Support us

Licensing & Partnering for Drug Forms of the Future Generation

[Category : - HEALTH]
[Viewed 1175 times]

rnAugust 13th 2018rnDear Sirrn Sub: Licensing & Partnering for Patent of Drug Forms of the Future GenerationrnrnYou : Are leaders in the Pharmaceutical arena having successfully rnpioneered the discovery of important drugs. rnrnBenefits : The drugs discovered and commercially marketed by you indeed have rnbeen the ones very specifically targeted to ensure excellent therapeutic end results.rnrnDrawbacks : To enable a Drug to perform it’s ideal best, it needs to have, apart rnfrom an effective therapeutic valuernrna) An Increased Bioabsorbtivityrnb) A High Retentivityrnc) A quick entry time into the blood stream and in turn to it’s target site and most importantlyrnd) The least possible toxicity.rnrnrnMy Role : I have, by the process of evolution been able to sight upon a simple rnsolution to a complex problem. rnrnBy a simple process of linking the conventional drug with a set of bioenhancers, I have been able to exponentially enhance it’srnrna) Bioabsorptivityrnb) Retentivity in the blood streamrnc) Solubility in turn ensuring it’s quicker entry into the blood stream rnand most importantly rnVASTLY help in reducing the toxicity of the conventional drug.rnrnrnModus Operandi: Bioenhancers like Alcohol (Ethanol) have been well documented to rnensure it’s quickest entry into the blood stream. rnrnLinking an alcohol molecule with a drug molecule to ensure it’s increased bioabsorption is also well known. rnI have, for the first time in the medical history, been successfully able to exponentially increase the number of reactive sites in a drug molecule. rnrnThis ensures one’s ability to increase the number of Bioenhancers that can be linked to a single drug molecule.rnrnMore the number of bioenhancers linked to a single drug molecule, more the ability of a drug to effectively transverse from the digestive tract to the blood stream and in turn to it’s target site to perform it’s role in the fastest and safest manner possible.rn rnAnother interesting feature of the linking of my set of bioenhancers to a given drug molecule is that the prodrug now formed remains in a completely soluble form in the varied pH conditions of the digestive tract without agglomerating / coagulating / precipitating when ingested orally. This ensures it being smaller than the pore size of the Intestinal Lining (The Prodrug molecule remains separate and smaller than even the wavelength of light) ensuring it’s best bioabsorption. rnUnique Benefits:-rnI. From the SCIENTIFIC viewpoint: rnMy discovery probably ensures the most effective way in which a drug orally ingested can be made to reach it’s target site. rnMUCH LOWER DOSAGE will help achieve the required therapeutic effect rn OR rnAN EQUIVALENT DOSAGE will help achieve MUCH IMPROVED therapeutic effect WITH MUCH REDUCED TOXICITY.rn II. From the COMMERCIAL viewpoint:rnI hold a valid patent in Indian, Australia and Canada as below.rnIndian Patent No. 236640rnAustralian Patent No. 2006264407,rnCanadian Patent : Approved and in the process of being numbered. rnWhile my patent application in Europe is progressing positively, it is currently held up awaiting my payment for the maintenance fee.rnrnMy discovery helps in synthesis of the MOST EFFECTIVE FORM OF PRODRUG (a new molecule) which safely gets metabolized to the conventionally known drug form by the Liver in the blood stream. The other by products being known and safely accredited pharmaceutical additives. rnrnYour incorporating of my discovery can help in YOUR EXCLUSIVELY MARKETING the NEW PRODRUG molecule till the expiry of it’s Patent life without any competition. rnrnIn simpler words a golden opportunity of EXCLUSIVELY MARKETING a known drug molecule ( new or old ) in an improved NEW PRODRUG FORM now awaits the Patent Purchaser.rn In case you wish to benefit from this unique discovery, please correspond back.rn Kind regardsrn rn R.Krishnanrn Quest Inculcatorrn rnPhone: 00 91-44-42012655rnEmail: [Use the button below to contact me] of Conceptrnrn PHARMACOKINETIC STUDY:rnrnImproving Bio-availability and vastly Reducing side effects (toxicity) of StatinsrnrnAs an example, the bioabsorption of improved form of my drug namely Conjugated Atorvastatin was compared with Atorvastatin Calcium the market standard, in Rabbits. Atorvastatin Calcium remains as a precipitate in the whole range of pH of the digestive track. In comparison my Conjugated Atorvastatin remains in a soluble form without agglomerating / precipitating / coagulating at every stage of the digestive track enabling higher bioabsorption as has been proved in a pharmacokinetic study conducted on Rabbits where the AUC of my Conjugated Atorvastatin was found to be 30% more, the Cmax 40% more, the mean residence time (MRT) 63% more and most importantly the Tmax being achieved in just half the time as compared to Atorvastatin Calcium, the reference drug used in the study. rnrnThe most interesting feature of my discovery is that while statins have been well documented to help reduce ONLY Cholesterol levels, my Conjugated Statins has SUPERIOR FEATURES INCLUDING rnrn1. REDUCING LIVER TOXICITY rn2. REDUCING TRIGYLCERIDESrn3. IMPROVING HDL (Good cholesterol) rn4. VASTLY REDUCING LDL & VLDL (bad Cholesterol)rn rnas is evident in the results of Pharmakodynamic studies tabulated. rnrnrnrn rn Summary of PHARMACODYNAMIC studies rn conducted on Rats. rnrnrnStatins Total Triglycerides HDL LDL VLDL SGPT SGOT Total Serum Serumrn Cholesterol Bilirubin Urea Creatininern mg/dL mg/dL mg/dL mg/dL mg/dL IU/L IU/L mg/dL mg/dL mg/dLrn SIMVASTATIN rnControl 64 44 20 39 9 22 46 0.16 23 0.59rnHigh Fat Feed 125 57 19 95 11 95 266 0.25 29 0.73rnHigh Fat Feed + Standard Simvastatin 66 58 40 14 12 107 174 0.65 81 0.63rnHigh Fat Feed + Conjugated Prodrug Simvastatin 59 19 45 10 4 76 170 0.16 33 0.36rn ATORVASTATIN rnControl 64 44 20 39 9 22 46 0.16 23 0.59rnHigh Fat Feed 125 57 19 95 11 95 266 0.25 29 0.73rnHigh Fat Feed + Standard Atorvastatin 80 42 24 16 9 92 262 0.27 36 0.69rnHigh Fat Feed + Conjugated Prodrug Atorvastatin 69 24 26 14 5 89 237 0.18 34 0.61rnPRAVASTATIN rnControl 64 44 20 39 9 22 46 0.16 23 0.59rnHigh Fat Feed 125 57 19 95 11 95 266 0.25 29 0.73rnHigh Fat Feed + Standard Pravastatin 74 80 47 11 16 104 250 0.57 36 0.73rnHigh Fat Feed + Conjugated Prodrug Pravastatin 64 43 48 6 9 100 207 0.47 36 0.68rnrnrnrnrnrnStatins Total Triglycerides HDL LDL VLDL SGPT SGOT Total Serum Serumrn Cholesterol Bilirubin Urea CreatininernEZETIMIBE rnControl 64 44 20 39 9 22 46 0.16 23 0.59rnHigh Fat Feed 125 57 19 95 11 95 266 0.25 29 0.73rnHigh Fat Feed + Standard Ezetimibe 80 120 46 10 24 103 305 0.46 89 0.68rnHigh Fat Feed + Conjugated Prodrug Ezetimibe 69 62 48 9 12 96 193 0.52 40 0.64rnPHYTOSTEROL rnControl 64 44 20 39 9 22 46 0.16 23 0.59rnHigh Fat Feed 125 57 19 95 11 95 266 0.25 29 0.73rnHigh Fat Feed + Standard Phytosterol 61 60 38 12 12 107 229 0.39 75 0.73rnHigh Fat Feed + Conjugated Prodrug Phytosterol 59 58 39 9 11 102 174 0.39 36 0.48rnROSUVASTATIN rnControl 64 44 20 39 9 22 46 0.16 23 0.59rnHigh Fat Feed 125 57 19 95 11 95 266 0.25 29 0.73rnHigh Fat Feed + Standard Rosuvastatin 50 64 27 10 13 111 321 0.72 45 0.87rnHigh Fat Feed + Conjugated Prodrug Rosuvastatin 43 46 26 7.5 9 101 300 0.31 40 0.8rn rn Effective rn rn Very Effecitve rn rnrnrn

email : reachus[at]novelproducts.in

Patent publications:

AU 2006264407

Asking price:

Make an offer

Rate this patent

Great invention
Viewed: 1175 times

Seller:

rkrishnan (India)

Ask a question
or start a negotiation

Contact the seller

Share on social media